• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Astrazeneca Plc Ord (OP: AZNCF )

    159.50 +3.22 (+2.06%)
    Streaming Delayed Price Updated: 10:51 AM EDT, Jul 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12,844
    Open 159.50
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 156.28
    Today's Range 159.50 - 159.50
    52wk Range 118.16 - 165.22
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 stocks that crushed earnings estimates and still tanked
    Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks 
    Via MarketBeat
    Exposures COVID-19
    AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization
    Earlier today, AstraZeneca plc (NASDAQ: AZN)  
    Via Benzinga

    Performance

    YTD
    +20.09%
    +20.09%
    1 Month
    +1.27%
    +1.27%
    3 Month
    +5.63%
    +5.63%
    6 Month
    +21.52%
    +21.52%
    1 Year
    +8.50%
    +8.50%

    More News

    Read More
    AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up
    Via Benzinga
    AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
    Via Benzinga
    AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
    Via Benzinga
    AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
    Via Benzinga
    AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
    Via Benzinga
    Why Are Pieris Pharmaceuticals Shares Tanking Today
    Via Benzinga
    AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions
    Via Benzinga
    AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder
    Via Benzinga
    AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes
    Via Benzinga
    Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
    Via Benzinga
    AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients
    Via Benzinga
    AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer
    Via Benzinga
    AstraZeneca's China Executive Seeks Loyalty to "Love the Communist Party" In China
    Via Benzinga
    One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
    Via Benzinga
    AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer
    Via Benzinga
    Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
    Via Benzinga
    FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug
    Via Benzinga
    FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
    Via Benzinga
    AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues
    Via Benzinga
    AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
    Via Benzinga
    Why AstraZeneca Shares Are Trading Higher Today?
    Via Benzinga
    Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay
    Via Benzinga
    AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.